In summary, previous clinical trials, such as the phase II study published in The New England Journal of Medicine (2016), reported that the most common AEs were mild to moderate skin reactions, gastrointestinal symptoms, and elevated CPK levels (Dombi et al., 2016). This evidence concerns the gene PIK3C2A and skin reaction.